MIL-86

重组全人源单抗MIL86

Report date: 2026/03/06 20:02:51

Base Information

Drug NameMIL-86
Drug Alias Name重组全人源单抗MIL86注射液MIL-86
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Mabworks Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Mabworks Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsHyperlipidemiasHyperlipoproteinemia Type II
Inactive IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A